Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Rescriptor: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Rescriptor - General Information

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. [PubChem]

 

Pharmacology of Rescriptor

Rescriptor is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Rescriptor binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Rescriptor does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Rescriptor.

 

Rescriptor for patients

Patients should be informed that RESCRIPTOR is not a cure for HIV-1
infection and that they may continue to acquire illnesses associated
with HIV-1 infection, including opportunistic infections. Treatment
with RESCRIPTOR has not been shown to reduce the incidence or frequency
of such illnesses, and patients should be advised to remain under the
care of a physician when using RESCRIPTOR. Patients should be advised
that the long-term effects of treatment with RESCRIPTOR are unknown at
this time. They should be advised that the use of RESCRIPTOR has not been
shown to reduce the risk of transmission of HIV-1.

 

Rescriptor Interactions

Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir,
Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin,
Ritanovir, Saquinavir.

 

Rescriptor Contraindications

RESCRIPTOR Tablets are contraindicated in patients with previously
demonstrated clinically significant hypersensitivity to any of the
components of the formulation.

 

Additional information about Rescriptor

Rescriptor Indication: For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted Mechanism Of Action: Rescriptor binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. Drug Interactions: Alprazolam The antiviral agent increases the effect and toxicity of benzodiazepineAmprenavir Decreased levels of delavirdine with increased levels of amprenavirAstemizole Increased risk of cardiotoxicity and arrhythmiasAtorvastatin The NNRT inhibitor increases the effect and toxicity of the statinCarbamazepine The anticonvulsant decreases the effect of delavirdineCisapride Increased risk of cardiotoxicity adn arrhythmiasDihydroergotamine The antiretroviral agent may increase the ergot derivative toxicityDihydroergotoxine The antiretroviral agent may increase the ergot derivative toxicityErgonovine The antiretroviral agent may increase the ergot derivative toxicityErgotamine The antiretroviral agent may increase the ergot derivative toxicityFosamprenavir Decreased levels of delavirdine with increased levels of amprenavirFosphenytoin The anticonvulsant decreases the effect of delavirdineIndinavir Increases the effect of indinavirLovastatin The NNRT inhibitor increases the effect and toxicity of the statinMethylergonovine The antiretroviral agent may increase the ergot derivative toxicityMethylphenobarbital The anticonvulsant decreases the effect of delavirdineMethysergide The antiretroviral agent may increase the ergot derivative toxicityMidazolam The antiviral agent increases the effect and toxicity of benzodiazepinePhenobarbital The anticonvulsant decreases the effect of delavirdinePhenytoin The anticonvulsant decreases the effect of delavirdineQuinupristin This combination presents an increased risk of toxicityRifabutin Rifabutin decreases the effect of delavirdineRifampin Rifampin decreases the effect of delavirdineRitonavir Increases the effect of ritonavirSaquinavir Increases the effect of saquinavir and hepatic toxicitySimvastatin The NNRT inhibitor increases the effect and toxicity of the statinSt. John's Wort St. John's Wort decreases the antiretroviral effectTerfenadine Increased risk of cardiotoxicity and arrhythmiasTriazolam The antiviral agent increases the effect and toxicity of benzodiazepineAluminium The antiacid decreases the effect of delavirdineBismuth The antiacid decreases the effect of delavirdineCalcium The antiacid decreases the effect of delavirdineMagnesium oxide The antiacid decreases the effect of delavirdineMagnesium The antiacid decreases the effect of delavirdine Food Interactions: Take without regard to meals. Generic Name: Delavirdine Synonyms: DLV; SPP Drug Category: Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors Drug Type: Small Molecule; Approved Other Brand Names containing Delavirdine: BhapDer; Rescriptor; Absorption: Rapidly absorbed Toxicity (Overdose): Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician. Protein Binding: 98% Biotransformation: Hepatic Half Life: 5.8 hours Dosage Forms of Rescriptor: Tablet Oral Chemical IUPAC Name: N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide Chemical Formula: C22H28N6O3S Delavirdine on Wikipedia: https://en.wikipedia.org/wiki/Delavirdine Organisms Affected: Human Immunodeficiency Virus